Summit Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
April 05 2018 - 6:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces
that Glyn Edwards, Chief Executive Officer, will present at the
H.C. Wainwright Global Life Sciences Conference on 10 April 2018 at
3:00pm CEST in Monte Carlo, Monaco.
A live audio webcast of the presentation will be
available through the Investors section on the Company's website,
www.summitplc.com. A replay of the webcast will be available from
the same location soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn
Edwards / Richard Pye (UK office) |
Tel: |
44
(0)1235 443 951 |
Erik
Ostrowski / Michelle Avery (US office) |
|
+1
617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44
(0)20 7213 0880 |
Liam
Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44
(0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
|
|
Panmure Gordon (Joint Broker) |
Tel: |
+44
(0)20 7886 2500 |
Freddy Crossley, Corporate Finance |
|
|
Tom
Salvesen, Corporate Broking |
|
|
|
|
|
MacDougall Biomedical Communications (US) |
Tel: |
+1
781 235 3060 |
Karen
Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44
(0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner |
|
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024